Jazz Pharmaceuticals Expands Portfolio with Redx Pharma’s KRAS Inhibitor

• Jazz Pharmaceuticals has entered into a definitive agreement with Redx Pharma.

• The agreement involves the acquisition of global rights to the KRAS inhibitor program, this move signifies a strategic expansion of Jazz Pharmaceuticals’ portfolio.

Jazz Pharmaceuticals has made a strategic move in the pharmaceutical industry by entering into a definitive agreement with Redx Pharma. This agreement involves the acquisition of global rights to the KRAS inhibitor program, a significant development in the field of contract manufacturing.

The deal was announced recently, marking a new chapter in the ongoing collaboration between the two pharmaceutical giants. The KRAS inhibitor program, previously under the stewardship of Redx Pharma, will now be globally managed by Jazz Pharmaceuticals.

“KRAS is a well-validated oncology target and there remains a high unmet need for innovation in this area based on challenges in developing molecules to target specific KRAS mutations. Redx has discovered a number of preclinical KRAS candidates and we plan to leverage our collective oncology development expertise to identify and advance the most promising molecules toward the clinic,” said Robert Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals. “This transaction further expands our early-stage oncology pipeline, and we are excited to explore novel approaches to improving treatment options for cancer patients.”

Lisa Anson, Chief Executive Officer of Redx, commented: “Once again, our distinguished expertise in medicinal chemistry has been recognized and we are pleased to secure another strategic transaction with Jazz, with whom we have a track record of collaboration. This agreement will allow us to collaborate on the advancement of novel KRAS inhibitors and we look forward to supporting Jazz in progressing these candidates through IND-enabling studies. Partnerships remain a key pillar of our corporate strategy, allowing us to advance what we believe are differentiated molecules in areas of high unmet need, while also creating long-term shareholder value through non-dilutive funding, with the upfront milestone payment from this agreement extending our current cash runway into 2025.”